Compare Gigacloud Technology Inc (GCT) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gigacloud Technology Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Gigacloud Technology Inc trades at $57.53 (market cap $2.06B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: Gigacloud Technology Inc is far larger — about 2.1× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Gigacloud Technology Inc is trading nearer its 52-week high, Maravai LifeSciences Holdings Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Gigacloud Technology Inc for 20 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| GCT | MRVI | |
|---|---|---|
Market Cap | $2.06B | $977.37M |
Volume | 820,423 | 2,742,564 |
Sector | Technology | Health |
52-Week High | $57.75 | $9.00 |
52-Week Low | $25.46 | $2.83 |
Typical Hold Time | 20 Days | 0 Days |
Enterprise Value | $2.19B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GCT trades at $57.03, down 1.23% today, with a bullish technical outlook from moving averages but bearish oscillators. The company demonstrates strong fundamentals with consistent earnings beats, 10.65% net margins, and robust 32.34% ROE. Recent news highlights institutional interest and analyst optimism despite insider selling activity. Revenue growth continues with 2026 projections showing $1.5B revenue and maintained profitability.
GCT presents a compelling investment case with attractive valuation multiples (P/E 13.58) and strong execution, though technical indicators show overbought conditions. Key risks include market volatility and competitive pressures, but analyst consensus remains bullish with 66.7% buy ratings and $32.50 price target suggesting significant upside potential from current levels.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gigacloud Technology Inc
Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
